CRP and hypercalcemia disease: In a pooled analysis of 276 patients from three clinical trials by JCOG–LSG, patients were divided into two groups based on performance status and hypercalcemia, and MST in these groups was 6.3 months and 17.8 months, respectively.13 Furthermore, a retrospective analysis of 1792 patients with acute or lymphoma ATL (2000–2013) aged 70 years or younger identified subtype (acute), performance status, hypercalcemia, C-reactive protein, and sIL-2R as prognostic factors.